Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines, vaccines franchises, support, and corporate functions 1973 and is headquartered in Paris, France.

CEO

Belén Garijo López

CEOBelén Garijo López

Employees

76,493

Employees76,493

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1973

Founded1973

Employees

76,493

Employees76,493

SNY Key Statistics

Market cap

116.15B

Market cap116.15B

Price-Earnings ratio

24.84

Price-Earnings ratio24.84

Dividend yield

3.64%

Dividend yield3.64%

Average volume

6.17M

Average volume6.17M

High today

$48.96

High today$48.96

Low today

$48.20

Low today$48.20

Open price

$48.89

Open price$48.89

Volume

2.36M

Volume2.36M

52 Week high

$52.68

52 Week high$52.68

52 Week low

$39.07

52 Week low$39.07

SNY News

TipRanks 6h

Sanofi Discloses October 31, 2026 Share and Voting Rights Figures

An update from Sanofi ( (FR:SAN) ) is now available. Sanofi, a French société anonyme with share capital of EUR 2,415,546,786, reported that on 31 October 2026...

TipRanks 7h

Sanofi Updates Long-Term Frexalimab Study as Investors Watch Multiple Sclerosis Pipeline

Sanofi SA (SNY) announced an update on their ongoing clinical study. Study Overview: Sanofi’s Phase 3 study, officially titled “A Phase 3 Extension Study to In...

TipRanks 7h

Sanofi Updates Fabry Disease Study: What Investors Should Know

Sanofi (SNYNF) announced an update on their ongoing clinical study. Study Overview: Sanofi’s study, officially titled “An Observational Study of Enzyme Replace...

Analyst ratings

60%

of 10 ratings

Buy

60%

Hold

40%

Sell

More SNY News

Simply Wall St 5d

Does Phase 1 Drug Cancellation Change The Bull Case For Nurix Therapeutics?

Sanofi informed Nurix Therapeutics that it has discontinued the Phase 1 trial of SAR448272 and terminated the STAT6 degrader program, removing any future milest...

TipRanks 6d

Novavax Earnings Call Signals Stronger Growth Ahead

Novavax ((NVAX)) has held its Q3 earnings call. Read on for the main highlights of the call. Novavax’s earnings call carried a strongly positive tone, as partn...

TipRanks 6d

Sanofi Advances Late-Stage Study of Belumosudil for Chronic Graft-versus-Host Disease

Sanofi SA (SNY) announced an update on their ongoing clinical study. Study Overview: Sanofi’s official study title is “A Parallel Group, Phase 3, Randomized, O...

Zacks 6d

NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline

Novavax (NVAX Quick QuoteNVAX - Free Report) recorded a loss of 19 cents per share in the third quarter of 2026, narrower than the Zacks Consensus Estimat...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.